Barroso Lívia Corrêa, Silveira Kátia Daniela, Lima Cristiano Xavier, Borges Valdinéria, Bader Michael, Rachid Milene, Santos Robson Augusto Souza, Souza Danielle Gloria, Simões E Silva Ana Cristina, Teixeira Mauro Martins
Laboratório de Imunofarmacologia, Departamento de Bioquímica e Imunologia, Instituto de Ciências Biológicas, UFMG, 31270-901 Belo Horizonte, MG, Brazil.
Int J Hypertens. 2012;2012:808726. doi: 10.1155/2012/808726. Epub 2012 Jan 29.
Renal ischemia and reperfusion (I/R) is the major cause of acute kidney injury in hospitalized patients. Mechanisms underlying reperfusion-associated injury include recruitment and activation of leukocytes and release of inflammatory mediators. In this study, we investigated the renal effects of acute administration of AVE0991, an agonist of Mas, the angiotensin-(1-7) receptor, the angiotensin-(1-7) receptor, in a murine model of renal I/R. Male C57BL/6 wild-type or Mas(-/-) mice were subjected to 30 min of bilateral ischemia and 24 h of reperfusion. Administration of AVE0991 promoted renoprotective effects, as seen by improvement of function, decreased tissue injury, prevention of local and remote leucocyte infiltration, and release of the chemokine, CXCL1. I/R injury was similar in WT and Mas(-/-) mice, suggesting that endogenous activation of this receptor does not control renal damage under baseline conditions. In conclusion, pharmacological interventions using Mas receptor agonists may represent a therapeutic opportunity for the treatment of renal I/R injury.
肾缺血再灌注(I/R)是住院患者急性肾损伤的主要原因。再灌注相关损伤的潜在机制包括白细胞的募集和激活以及炎症介质的释放。在本研究中,我们在肾I/R小鼠模型中研究了急性给予AVE0991(Mas的激动剂,Mas是血管紧张素-(1-7)受体)对肾脏的影响。雄性C57BL/6野生型或Mas(-/-)小鼠经历30分钟的双侧缺血和24小时的再灌注。给予AVE0991可促进肾脏保护作用,表现为功能改善、组织损伤减轻、局部和远处白细胞浸润的预防以及趋化因子CXCL1的释放减少。野生型和Mas(-/-)小鼠的I/R损伤相似,这表明在基线条件下该受体的内源性激活并不控制肾损伤。总之,使用Mas受体激动剂的药物干预可能为治疗肾I/R损伤提供一个治疗机会。